Technology
Health
Biotechnology
Chimerix
$3.559876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.09 (2.56%) Today
-$0.05 (-1.39%) After Hours
Why Robinhood?
You can buy or sell Chimerix and other stocks, options, ETFs, and crypto commission-free!
About
Chimerix, Inc. Common Stock, also called Chimerix, is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Read More Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Employees
59
Headquarters
Durham, North Carolina
Founded
2000
Market Cap
183.69M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
327.05K
High Today
$3.65
Low Today
$3.50
Open Price
$3.50
Volume
405.87K
52 Week High
$5.04
52 Week Low
$1.74
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2013 IPO
US
North America
News
Seeking AlphaMay 9
Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Michelle LaSpaluto – Investor Relations Mike Sherman – President and Chief Executive Officer Garrett Nichols – Chief Medical Officer Tim Trost – Chief Financial Officer Mike Andriole – Chief Business Officer Conference Call Participants Ed White – H.C. Kenneth Atkins – Cowen Operator Good morning. Welcome to the Chimerix conference call discussing the financial results of the first quarter of...
Price Paid on Robinhood
13% Lower
Right Now
52 Week Low
$1.74
Average Price Paid
$4.06
52 Week High
$5.04
Earnings
-$0.47
-$0.41
-$0.35
-$0.29
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 8, Pre-Market